Search results
Exelixis (EXEL) Down 6.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 5 days agoA filing for...TKI), is being evaluated in three ongoing pivotal trials, STELLAR-303, -304 and -305,...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoOneOncology Highlights Research Contributions at 2024 ASCO Annual Meeting PR Newswire NASHVILLE, Tenn., May 30, 2024 NASHVILLE, Tenn., May 30, 2024 /PRNewswire/ -- OneOncology, the fastest growing platform for independent oncology practices, is
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
WROC Rochester· 7 days agoUSA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years...
Health & Wellness: Early detection provides pivotal impact in treating skin cancer
Provo Daily Herald· 6 days agoThe statistics on skin cancer are indeed sobering. One in five Americans will be diagnosed with skin...
Statins May Help Prevent Certain Forms of Cancer
Healthline· 4 days agoScientists believe statins, cheap cholesterol-lowering medications, could be used for cancer prevention. Statins have anti-inflammatory effects, which...
Mercy Bioanalytics Pushing Forward with Plans to Market Ovarian Cancer Blood Test
GenomeWeb News· 7 days agoExtracellular vesicle diagnostics firm Mercy Bioanalytics is making progress in its plans to market and eventually garner US Food and Drug Administration approval for a novel ovarian
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic...
Digital Journal· 5 days agoPHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology ...
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1...
Morningstar· 3 days agoNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO ...